Reliance Biotech Arm Invests $2M in Innervate PET Imaging with $250M Neuroblastoma Focus
EZRA•Reliance Global Group’s biotech arm LifeSci Global invested $2 million to buy 421,053 Innervate Radiopharmaceuticals shares at $4.75, funding $500,000 at closing with rights to accelerate funding. The transaction secures a PET imaging platform targeting a $250 million neuroblastoma market plus potential $1 billion cardiovascular and neurodegenerative opportunities.
1. Investment Details
LifeSci Global, the biotech division of Reliance Global Group, acquired 421,053 shares of Innervate Radiopharmaceuticals at $4.75 per share, representing a $2.0 million commitment. The company funded $500,000 at closing and retains a unilateral right to accelerate further capital deployment as development milestones are met.
2. Innervate’s Lead Asset
Innervate’s lead candidate, 18F-mFBG, is a next-generation PET imaging agent designed to improve neuroblastoma diagnostics with higher-resolution images, faster scan times and enhanced lesion detection compared to the 123I-mIBG SPECT standard of care. The program is in late-stage development with pivotal efficacy and safety studies underway toward regulatory submission.
3. Market Opportunity
The neuroblastoma application alone represents an estimated $250 million annual global revenue opportunity, while broader cardiovascular and neurodegenerative markets could each exceed $1 billion. A Rare Pediatric Disease Priority Review Voucher may provide additional monetizable value if awarded upon approval.
4. Strategic Rationale
This investment advances Reliance’s strategy to build exposure to high-growth healthcare platforms through staged capital allocation. The deal offers near-term oncology upside with substantial long-term expansion potential, aligning with the company’s aim to drive shareholder value through innovation-driven biotech assets.
